ClinicalTrials.gg
CompletedNCT03976323Updated Sep 28, 2026Results posted

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

A Phase 3 interventional study of Pembrolizumab and Pemetrexed in Carcinoma, Nonsquamous Non-small-cell Lung, sponsored by Merck Sharp & Dohme LLC. Completed at 178 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Study completion movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,003
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.

Enrollment
6th of 358
1,003 · median 48
Started
2019
with 20 others
Phase 3
49 of 402
6 open now
Registered
261st of 402
by date

Among the 402 studies in Carcinoma with a site in United States, this one is the 6th largest by enrollment of the 358 interventional ones that give a count, is one of 21 that started in 2019, is one of 49 in phase 3, and was the 261st registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 402 studies in Carcinoma with a site in United States, or all of them as a file.
02

Study summary

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).

Read the detailed description

This study has 2 phases: an Induction Phase of up to \~4 Cycles (up to \~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to \~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to \~35 cycles (up to \~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.

Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to \~35 cycles of pembrolizumab (up to \~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to \~17 cycles (up to \~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.

03

Conditions studied

  • Carcinoma, Nonsquamous Non-small-cell Lung

Browse trials for

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a or cytologically confirmed diagnosis nonsquamous NSCLC.
  2. Have stage IV nonsquamous NSCLC.
  3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.
  4. Have based on 1.1.
  5. Have provided sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.

    Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.

  6. Have a of at least 3 months.
  7. Have a performance status of 0 or 1 on the (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.
  8. Have not received prior systemic treatment for their advanced/ NSCLC.
  9. Have adequate organ function.
  10. Male and female participants who are not pregnant and of must follow guidance during the treatment period and for 180 days afterwards.
  11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.

Exclusion criteria

Exclusion Criteria:

  1. Has predominantly squamous cell histology NSCLC.
  2. Has a known additional that is progressing or has progressed within the past 3 years requiring active treatment.
  3. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  4. Has a severe (≥Grade 3) to pembrolizumab and/or any of its .
  5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.
  6. Has an active disease that has required systemic treatment in past 2 years.
  7. Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy.
  8. Has a known history of (HIV) infection, a known history of infection, or known active virus infection.
  9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
  10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
  11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
  13. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,003 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib

    For the Induction Phase, participants receive 4 cycles (up to \~12 weeks \[cycle = 3 weeks\]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to \~35 cycles (up to \~2 years \[cycle = 3 weeks\]).

    Biological: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin · Drug: Olaparib

  • Active comparator
    Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed

    For the Induction Phase, participants receive 4 cycles (up to \~12 weeks \[cycle = 3 weeks\]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m\^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to \~35 cycles (up to \~2 years \[cycle = 3 weeks\]).

    Biological: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • IV infusion

    Also known as: ALIMTA®

  • IV infusion

    Also known as: PARAPLATIN®

  • IV infusion

    Also known as: PLATINOL®, PLATINOL®-AQ

  • Oral Tablet

    Also known as: LYNPARZA®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~31 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~51 months

Secondary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

    Time frame: Up to ~5 years

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

    Time frame: Up to ~5 years

  3. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Baseline and Week 24

  4. Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.

    Time frame: Up to ~24 months

  5. Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Baseline and Week 24

  6. TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~24 months

  7. Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Baseline and Week 24

  8. TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~24 months

  9. Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Baseline and Week 24

  10. TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~24 months

  11. Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Baseline and Week 24

  12. TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

    Time frame: Up to ~24 months

07

Results

Posted Feb 6, 2025

Participant flow

Induction Phase
Participant flow — Induction Phase
MilestonePembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Started100300
Completed67200
Not completed33100
Withdrew: Failure to meet maintenance randomization criteria25100
Withdrew: Death8000
Maintenance Phase
Participant flow — Maintenance Phase
MilestonePembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Started0337335
Treated0337332
Received second course of pembrolizumab0713
Completed000
Not completed0337335
Withdrew: Participant ongoing in study010097
Withdrew: Withdrawal by subject093
Withdrew: Physician decision001
Withdrew: Death0228234

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~31 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Progression-free Survival (PFS)7.1 (5.6 to 8.7)8.3 (6.9 to 11.5)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.8721 (One-sided p-value based on log-rank test stratified by Eastern Cooperative Oncology Group (ECOG) at pre-randomization visit, response at randomization and baseline PD-L1 status.) · Hazard ratio (hr): 1.12 · 95% CI 0.92 to 1.36Based on Cox regression model with Efron's method of tie handling and with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization and baseline PD-L1 status.
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~51 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Overall Survival (OS)20.7 (18.0 to 24.8)23.0 (19.0 to 26.4)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.6649 (One-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization and baseline PD-L1 status.) · Hazard ratio (hr): 1.04 · 95% CI 0.87 to 1.25Based on Cox regression model with Efron's method of tie handling and with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization and baseline PD-L1 status.
SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Time frame:
Up to ~5 years

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.

Time frame:
Up to ~5 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
Scores on a scalePembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score-5.34 (-7.78 to -2.90)-3.44 (-5.90 to -0.98)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · t-test, 2 sided · p = 0.2533 (Two-sided p-value based on t test.) · Difference in least squares (ls) means: -1.90 · 95% CI -5.16 to 1.36Based on constrained longitudinal data analysis model (cLDA) model with PRO scores as response variable with covariates for treatment by time interaction, stratification factors, response at randomization and baseline PD-L1 expression as covariates.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.

Time frame:
Up to ~24 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score19.81 (15.97 to NA)17.28 (9.46 to NA)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.8125 (Two-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.) · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.24Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.
SecondaryChange From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
Scores on a scalePembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score-1.98 (-4.90 to 0.94)-1.82 (-4.77 to 1.12)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · t-test, 2 sided · p = 0.9364 (Two-sided p-value based on t test.) · Difference in ls means: -0.16 · 95% CI -4.02 to 3.71Based on cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors, response at randomization, and baseline PD-L1 expression as covariates.
SecondaryTTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~24 months
Reported as:
Median · Months
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.3782 (Two-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.) · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.17Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.
SecondaryChange From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
Scores on a scalePembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score-0.82 (-3.25 to 1.61)-0.47 (-2.92 to 1.98)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · t-test, 2 sided · p = 0.8285 (Two-sided p-value based on t test.) · Difference in ls means: -0.35 · 95% CI -3.54 to 2.83Based on cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors, response at randomization, and baseline PD-L1 expression as covariates.
SecondaryTTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~24 months
Reported as:
Median · Months
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.6272 (Two-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.) · Hazard ratio (hr): 1.08 · 95% CI 0.78 to 1.51Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.
SecondaryChange From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Scores on a scalePembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score-0.16 (-3.07 to 2.76)1.35 (-1.60 to 4.31)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · t-test, 2 sided · p = 0.4422 (Two-sided p-value based on t test.) · Difference in ls means: -1.51 · 95% CI -5.38 to 2.35Based on cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors, response at randomization, and baseline PD-L1 expression as covariates.
SecondaryTTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~24 months
Reported as:
Median · Months
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.9156 (Two-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.) · Hazard ratio (hr): 0.98 · 95% CI 0.74 to 1.31Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.
SecondaryChange From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
Scores on a scalePembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score-2.79 (-4.92 to -0.65)-2.78 (-4.93 to -0.62)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · t-test, 2 sided · p = 0.9962 (Two-sided p-value based on t test.) · Difference in ls means: -0.01 · 95% CI -2.94 to 2.93Based on cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors, response at randomization, and baseline PD-L1 expression as covariates.
SecondaryTTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.

Time frame:
Up to ~24 months
Reported as:
Median · Months
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
MonthsPembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score20.96 (13.34 to NA)NA (17.28 to NA)
Statistical analysis
  • Pembrolizumab + Olaparib (Maintenance Phase) vs Pembrolizumab + Pemetrexed (Maintenance Phase) · Log Rank · p = 0.5517 (Two-sided p-value based on log-rank test stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.) · Hazard ratio (hr): 1.08 · 95% CI 0.83 to 1.40Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG at pre-randomization visit, response at randomization, and baseline PD-L1 expression.

Adverse events

Collected over Up to ~51 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)116/1,003 (11.6%)235/1,003 (23.4%)872/1,003 (86.9%)
Pembrolizumab (First Course) + Olaparib (Maintenance Phase)233/337 (69.1%)118/337 (35%)298/337 (88.4%)
Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase)233/335 (69.6%)125/332 (37.7%)289/332 (87%)
Pembrolizumab (Second Course) + Olaparib (Maintenance Phase)0/7 (0%)0/7 (0%)2/7 (28.6%)
Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase)2/13 (15.4%)1/13 (7.7%)9/13 (69.2%)
Most frequent serious events
Showing 10 of 293
Most frequent serious events
EventPembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab (First Course) + Olaparib (Maintenance Phase)Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase)Pembrolizumab (Second Course) + Olaparib (Maintenance Phase)Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase)
Respiratory tract infectionInfections and infestations1/10031/3370/3320/71/13
COVID-19 pneumoniaInfections and infestations9/10036/33717/3320/70/13
PneumoniaInfections and infestations23/100314/33711/3320/70/13
PneumonitisRespiratory, thoracic and mediastinal disorders7/10037/33710/3320/70/13
AnaemiaBlood and lymphatic system disorders24/10039/3378/3320/70/13
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/10037/3370/3320/70/13
ThrombocytopeniaBlood and lymphatic system disorders18/10030/3372/3320/70/13
COVID-19Infections and infestations2/10036/3372/3320/70/13
DeathGeneral disorders8/10033/3375/3320/70/13
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/10033/3375/3320/70/13
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab (First Course) + Olaparib (Maintenance Phase)Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase)Pembrolizumab (Second Course) + Olaparib (Maintenance Phase)Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase)
AnaemiaBlood and lymphatic system disorders385/1003122/337125/3321/72/13
NauseaGastrointestinal disorders310/100381/33763/3320/70/13
NeutropeniaBlood and lymphatic system disorders235/100357/33732/3320/70/13
FatigueGeneral disorders140/100358/33754/3320/70/13
ThrombocytopeniaBlood and lymphatic system disorders114/100357/33735/3320/70/13
ConstipationGastrointestinal disorders169/100321/33739/3320/70/13
Aspartate aminotransferase increasedInvestigations81/100328/33755/3320/70/13
Alanine aminotransferase increasedInvestigations110/100331/33752/3320/70/13
Decreased appetiteMetabolism and nutrition disorders155/100352/33752/3320/71/13
CoughRespiratory, thoracic and mediastinal disorders36/100333/33738/3320/72/13

Baseline characteristics

Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase): All participants allocated to the pembrolizumab + Pemetrexed + Platinum Therapy arm in the Induction phase but not randomized into the maintenance phase; Pembrolizumab + Olaparib (Maintenance Phase): All participants randomized to the Pembrolizumab + Olaparib arm post Induction Phase; Pembrolizumab + Pemetrexed (Maintenance Phase): All participants randomized to the Pembrolizumab + Pemetrexed arm post Induction Phase.

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
Mean63.3 ± 9.461.6 ± 8.661.8 ± 9.862.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
Female109110109328
Male222227226675
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
Hispanic or Latino595067176
Not Hispanic or Latino246263253762
Unknown or Not Reported26241565
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
American Indian or Alaska Native54110
Asian569172219
Native Hawaiian or Other Pacific Islander0224
Black or African American94821
White236218234688
More than one race117927
Unknown or Not Reported1411934
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline of Maintenance Phase
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline of Maintenance Phase(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
Grade 00142135277
Grade 10195200395
Response at Baseline of Maintenance Phase
Response at Baseline of Maintenance Phase(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
Complete Response (CR)/Partial Response (PR)0189192381
Stable Disease (SD)0148143291
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline of Maintenance Phase
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline of Maintenance Phase(Participants)Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase)Pembrolizumab + Olaparib (Maintenance Phase)Pembrolizumab + Pemetrexed (Maintenance Phase)Total
TPS<50%0228223451
TPS ≥50%0109110219
Not Evaluable0011
Missing0011
08

Study locations

178 sites
  • Alabama Oncology Bruno Cancer Center ( Site 0001)
    Birmingham, Alabama 35205, United States
  • Northwest Alabama Cancer Center, PC ( Site 0002)
    Muscle Shoals, Alabama 35661, United States
  • Disney Family Cancer Center ( Site 0005)
    Burbank, California 91505, United States
  • Boca Raton Regional Hospital ( Site 0018)
    Boca Raton, Florida 33486, United States
  • Mid-Florida Cancer Centers ( Site 0022)
    Orange City, Florida 32763, United States
  • Moffitt Cancer Center ( Site 0024)
    Tampa, Florida 33612, United States
  • Columbus Regional Research Institute ( Site 0098)
    Columbus, Georgia 31904, United States
  • Mount Sinai Hospital Medical Center ( Site 0032)
    Chicago, Illinois 60608, United States
  • Oncology of Northshore ( Site 0033)
    Rolling Meadows, Illinois 60008, United States
  • Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
    Merrillville, Indiana 46410, United States
  • Medstar Good Samaritan Hospital ( Site 0040)
    Baltimore, Maryland 21239, United States
  • Barbara Ann Karmanos Cancer Institute ( Site 0041)
    Detroit, Michigan 48201, United States
  • Hattiesburg Clinic ( Site 0045)
    Hattiesburg, Mississippi 39401, United States
  • Frontier Oncology ( Site 0080)
    Billings, Montana 59102, United States
  • Bozeman Health Deaconness Cancer Center ( Site 0046)
    Bozeman, Montana 59715, United States
  • Waverly Hematology Oncology ( Site 0081)
    Cary, North Carolina 27518, United States
  • Thompson Cancer Survival Center ( Site 2812)
    Knoxville, Tennessee 37916, United States
  • University of Tennessee Medical Center Knoxville ( Site 0060)
    Knoxville, Tennessee 37920, United States
  • Renovatio Clinical ( Site 0062)
    The Woodlands, Texas 77380, United States
  • Cancer Care Northwest ( Site 0071)
    Spokane Valley, Washington 99216, United States
  • Hospital Italiano Regional del Sur ( Site 0509)
    Bahía Blanca, Buenos Aires B8001HXM, Argentina
  • Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Hospital Britanico de Buenos Aires ( Site 0500)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1280AEB, Argentina
  • Instituto Medico Rio Cuarto ( Site 0501)
    Río Cuarto, Córdoba Province X5800AEV, Argentina
  • Centro Oncológico de Rosario ( Site 0507)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Centro Medico San Roque ( Site 0506)
    San Miguel de Tucumán, Tucumán Province T4000IAK, Argentina
  • Clínica Universitaria Reina Fabiola ( Site 0505)
    Córdoba, X5004SHP, Argentina
  • Sanatorio Privado San Geronimo S.R.L ( Site 0510)
    Santa Fe, S3000AOL, Argentina
  • Liverpool Hospital ( Site 1201)
    Liverpool, New South Wales 2170, Australia
  • Southern Medical Day Care Centre ( Site 1200)
    Wollongong, New South Wales 2500, Australia
  • Townsville General Hospital ( Site 1202)
    Townsville, Queensland 4814, Australia
  • Monash Cancer Centre ( Site 1205)
    Clayton, Victoria 3168, Australia
  • Social Medical Center - Otto Wagner Hospital ( Site 1301)
    Vienna, State of Vienna 1145, Austria
  • Innsbruck LKH ( Site 1302)
    Innsbruck, Tyrol 6020, Austria
  • Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
    Linz, Upper Austria 4020, Austria
  • Klinikum Wels-Grieskirchen ( Site 1304)
    Wels, Upper Austria 4600, Austria
  • Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
    Vienna, 1210, Austria
  • Instituto do Cancer do Ceara ( Site 0201)
    Fortaleza, Ceará 60351-030, Brazil
  • Hospital Sao Rafael ( Site 0212)
    Salvador, Estado de Bahia 41253-190, Brazil
  • Oncologica do Brasil ( Site 0210)
    Belém, Pará 66053-000, Brazil
  • Hospital Tacchini ( Site 0208)
    Bento Gonçalves, Rio Grande do Sul 95700-000, Brazil
  • Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209)
    Porto Alegre, Rio Grande do Sul 90050-170, Brazil
  • Saint Gallen Instituto de Oncologia ( Site 0206)
    Santa Cruz do Sul, Rio Grande do Sul 96810-110, Brazil
  • YNOVA Pesquisa Clinica ( Site 0215)
    Florianópolis, Santa Catarina 88020-210, Brazil
  • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202)
    Itajaí, Santa Catarina 88301-220, Brazil
  • Centro de Hematologia e Oncologia ( Site 0205)
    Joinville, Santa Catarina 89201-260, Brazil
  • Hospital de Base de Sao Jose de Rio Preto ( Site 0204)
    Sao Jose Rio Preto, São Paulo 15080-000, Brazil
  • Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
    Rio de Janeiro, 20231-050, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
    São Paulo, 01246-000, Brazil
  • BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
    São Paulo, 01321-001, Brazil
  • Hospital Paulistano - Amil Clinical Research ( Site 0207)
    São Paulo, 01321-001, Brazil
  • Lions Gate Hospital ( Site 0106)
    North Vancouver, British Columbia V7L 2L7, Canada
  • BC Cancer - Victoria ( Site 0109)
    Victoria, British Columbia V8R 6V5, Canada
  • Queen Elizabeth II Health Sciences Centre ( Site 0107)
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Health Sciences North Research Institute ( Site 0115)
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Waterloo Regional Health Network (WRHN) ( Site 0117)
    Kitchener, Ontario N2G 1G3, Canada
  • Stronach Regional Cancer Centre ( Site 0101)
    Newmarket, Ontario L3Y 2P9, Canada
  • CISSS de la Monteregie-Centre ( Site 0114)
    Greenfield Park, Quebec J4V 2H1, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105)
    Montreal, Quebec H2X 3E4, Canada
  • CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110)
    Montreal, Quebec H3T 1M5, Canada
  • Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104)
    Rimouski, Quebec G5L 5T1, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604)
    Medellín, Antioquia 050030, Colombia
  • Clinica de la Costa S.A.S. ( Site 0608)
    Barranquilla, Atlántico 080020, Colombia
  • Administradora Country S.A. ( Site 0603)
    Bogotá, Bogota D.C. 110221, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601)
    Bogotá, Bogota D.C. 111321, Colombia
  • Institut De Cancerologie De Lorraine ( Site 1409)
    Vandœuvre-lès-Nancy, Ain 54519, France
  • Centre Hospitalier De Chauny ( Site 1411)
    Chauny, Aisne 02300, France
  • CHU Caen ( Site 1406)
    Caen, Calvados 14033, France
  • CHU Angers ( Site 1405)
    Angers, Maine-et-Loire 49100, France
  • Hopital Robert Schuman ( Site 1402)
    Vantoux, Moselle 57070, France
  • Centre Jean Perrin ( Site 1407)
    Clermont-Ferrand, Puy-de-Dome 63011, France
  • Centre Hospitalier de Pau ( Site 1412)
    Pau, Pyrenees-Atlantiques 64000, France
  • CHU de Rouen ( Site 1403)
    Rouen, Seine-Maritime 76000, France
  • Hopital d'Instruction des Armees Begin ( Site 1413)
    Saint-Mandé, Val-de-Marne 94163, France
  • Studienzentrum Aschaffenburg ( Site 1525)
    Aschaffenburg, Bavaria 63739, Germany
  • Klinikum der LMU ( Site 1500)
    Munich, Bavaria 80336, Germany
  • Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523)
    Munich, Bavaria 81925, Germany
  • Universitaetsklinikum Regensburg ( Site 1512)
    Regensburg, Bavaria 93053, Germany
  • Klinikum Wuerzburg Mitte gGmbH ( Site 1509)
    Würzburg, Bavaria 97074, Germany
  • Universitaetsklinikum Frankfurt ( Site 1513)
    Frankfurt am Main, Hesse 60590, Germany
  • Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501)
    Immenhausen, Hesse 34376, Germany
  • Universitaetsmedizin Goettingen ( Site 1507)
    Göttingen, Lower Saxony 37075, Germany
  • Universitaetsklinikum Bonn ( Site 1524)
    Bonn, North Rhine-Westphalia 53127, Germany
  • Kliniken Essen Mitte ( Site 1517)
    Essen, North Rhine-Westphalia 45136, Germany
  • InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514)
    Koblenz, Rhineland-Palatinate 56068, Germany
  • Helios Klinikum Erfurt GmbH ( Site 1502)
    Erfurt, Thuringia 99089, Germany
  • Katholisches Marienkrankenhaus gGmbH ( Site 1522)
    Hamburg, 22087, Germany
  • National Hospital Organization Nagoya Medical Center ( Site 0806)
    Nagoya, Aichi-ken 460-0001, Japan
  • Aichi Cancer Center ( Site 0803)
    Nagoya, Aichi-ken 464-8681, Japan
  • National Cancer Center Hospital East ( Site 0801)
    Kashiwa, Chiba 2778577, Japan
  • Kanazawa University Hospital ( Site 0811)
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Kanagawa Cancer Center ( Site 0807)
    Yokohama, Kanagawa 241-8515, Japan
  • Sendai Kousei Hospital ( Site 0812)
    Sendai, Miyagi 981-0914, Japan
  • Kansai Medical University Hospital ( Site 0804)
    Hirakata, Osaka 573-1191, Japan
  • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813)
    Sakai, Osaka 591-8555, Japan
  • Shizuoka Cancer Center ( Site 0802)
    Suntogun, Shizuoka 411-8777, Japan
  • National Hospital Organization Kyushu Medical Center ( Site 0805)
    Fukuoka, 8108563, Japan
  • Niigata Cancer Center Hospital ( Site 0808)
    Niigata, 951-8566, Japan
  • Okayama University Hospital ( Site 0810)
    Okayama, 700-8558, Japan

Showing the first 100 of 178 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gray JE, Schenker M, Sendur MAN, Leonova V, Kowalski D, Kato T, Orlova R, Yang JC, Langleben A, Pilz A, Ungureanu A, Mak MP, De Angelis F, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM. The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2025 Feb;20(2):219-232. doi: 10.1016/j.jtho.2024.10.026. Epub 2024 Nov 7. PubMed 39521434 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2024, 55 months.

Results were first posted in Feb 2025, 11 months after primary completion.

Of 35 phase 3 interventional studies under Carcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 82. This study's 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2019
First posted
Jun 6, 2019
StartActual
Jun 28, 2019
Primary completionActual
Feb 7, 2024
CompletionActual
Jan 30, 2026
Results first posted
Feb 6, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jan 29, 2026→Jan 30, 2026
Sep 28, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedHas history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Study completion Jan 29, 2026→Jan 30, 2026
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedHas history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03976323
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jun 28, 2019
Primary completion
Feb 7, 2024
Completion
Jan 30, 2026
Results posted
Feb 6, 2025
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion